DOCSLIB.ORG

Expanded Preventive Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

navitus.com Share a Clear View Expanded Preventive Drug List Updated January 2018 Your employer is making an effort to reduce your health care costs by giving you tools to help you stay healthy and productive. Below are the medications your employer has chosen to be included on your Preventive Drug List. These medications help protect against or manage some high risk medical conditions. Taking these medications as directed by your prescriber can help avoid serious health problems. That may mean fewer doctor visits and hospitalizations, reducing your total health care costs. In the drug list below, generic drugs are shown in lowercase type. Brand name drugs are shown in uppercase type. ANTIANGINAL AGENTS albuterol neb soln 0.5% isosorbide dinitrate SL tab albuterol neb soln 0.63mg isosorbide dinitrate tab albuterol neb soln 1.25mg isosorbide mononitrate ER tab albuterol sulfate ER tab isosorbide mononitrate tab albuterol sulfate syrup nitroglycerin lingual spray albuterol sulfate tab nitroglycerin patch albuterol/ipratropium neb soln nitroglycerin SL tab aminophylline tab nitroglycerin SR cap budesonide inh susp ANTIARRHYTHMICS ipratropium neb soln amiodarone tab levalbuterol neb soln disopyramide cap montelukast chew tab disopyramide ER cap montelukast granule pack dofetilide cap montelukast tab flecainide tab terbutaline sulfate tab mexiletine cap theophylline CR tab propafenone ER cap theophylline ER tab propafenone tab theophylline soln quinidine gluconate CR tab zafirlukast tab ANTIASTHMATIC AND BRONCHODILATOR zileuton ER tab AGENTS ANTICOAGULANTS albuterol neb soln 0.083% enoxaparin inj • Note: The list is subject to change and not all drugs listed may be covered on your formulary. Please refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com N3935-0418 navitus.com Share a Clear View fondaparinux inj topiramate sprinkle cap warfarin tab topiramate tab ANTICONVULSANTS valproic acid cap carbamazepine chew tab valproic acid syrup carbamazepine ER cap zonisamide cap carbamazepine ER tab ANTIDEPRESSANTS carbamazepine susp amitriptyline tab carbamazepine tab bupropion ER tab clonazepam ODT bupropion tab clonazepam tab bupropion XL tab divalproex ER tab citalopram soln divalproex sodium DR tab citalopram tab divalproex sprinkle cap clomipramine cap ethosuximide cap desipramine tab ethosuximide soln doxepin cap felbamate susp doxepin conc felbamate tab duloxetine EC cap gabapentin cap escitalopram soln gabapentin soln escitalopram tab gabapentin tab fluoxetine cap lamotrigine chew tab fluoxetine soln lamotrigine ER tab fluoxetine tab lamotrigine ODT fluvoxamine ER cap lamotrigine ODT kit fluvoxamine tab lamotrigine tab imipramine pamoate cap levetiracetam ER tab imipramine tab levetiracetam soln mirtazapine ODT levetiracetam tab mirtazapine tab oxcarbazepine susp nefazodone tab 50mg, 250mg oxcarbazepine tab nortriptyline cap phenytoin cap paroxetine ER tab phenytoin chew tab paroxetine tab phenytoin susp phenelzine tab primidone tab protriptyline tab tiagabine tab sertraline conc • Note: The list is subject to change. Please always refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com navitus.com Share a Clear View sertraline tab fenofibrate tab tranylcypromine tab fluvastatin cap trazodone tab gemfibrozil tab trimipramine cap lovastatin tab venlafaxine ER cap omega-3-acid ethyl esters cap venlafaxine ER tab pravastatin tab ANTIDIABETICS rosuvastatin tab acarbose tab rosuvastatin tab 20mg glimepiride tab simvastatin tab glipizide ER tab ANTIHYPERTENSIVES glipizide tab amlodipine/benazepril cap glipizide/metformin tab amlodipine/valsartan tab glyburide micronized tab amlodipine/valsartan/ glyburide tab hydrochlorothiazide tab glyburide/metformin tab atenolol/chlorthalidone tab metformin ER tab benazepril tab metformin tab benazepril/hydrochlorothiazide tab miglitol tab bisoprolol/hydrochlorothiazide tab nateglinide tab candesartan tab pioglitazone tab candesartan/hydrochlorothiazide tab pioglitazone/glimepiride tab captopril tab pioglitazone/metformin tab clonidine patch repaglinide tab clonidine tab tolazamide tab doxazosin tab ANTIHYPERLIPIDEMICS enalapril tab atorvastatin tab enalapril/hydrochlorothiazide tab cholestyramine lite powder eplerenone tab cholestyramine lite powder pack fosinopril tab cholestyramine powder fosinopril/hydrochlorothiazide tab cholestyramine powder pack guanfacine IR tab colestipol granule hydralazine tab colestipol powder packet irbesartan tab colestipol tab irbesartan/hydrochlorothiazide tab ezetimibe/simvastatin tab lisinopril tab fenofibrate cap lisinopril/hydrochlorothiazide tab • Note: The list is subject to change. Please always refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com navitus.com Share a Clear View losartan tab acebutolol cap losartan/hydrochlorothiazide tab atenolol tab methyldopa tab betaxolol tab methyldopa/hydrochlorothiazide tab bisoprolol tab metoprolol/hydrochlorothiazide tab carvedilol tab minoxidil tab labetalol tab moexipril tab metoprolol ER tab moexipril/hydrochlorothiazide tab metoprolol tab nadolol/bendroflumethiazide tab nadolol tab perindopril tab pindolol tab phenoxybenzamine cap propranolol ER cap prazosin cap propranolol tab propranolol/hydrochlorothiazide tab sotalol AF tab quinapril tab sotalol tab quinapril/hydrochlorothiazide tab timolol maleate tab ramipril cap CALCIUM CHANNEL BLOCKERS telmisartan tab amlodipine tab telmisartan/amlodipine tab diltiazem ER cap terazosin cap diltiazem ER tab trandolapril tab diltiazem tab trandolapril/ verapamil ER tab felodipine ER tab valsartan tab isradipine cap valsartan/hydrochlorothiazide tab nicardipine cap ANTINEOPLASTICS AND ADJUNCTIVE nifedipine cap THERAPIES nifedipine ER tab anastrozole tab nimodipine cap bicalutamide tab nisoldipine ER tab exemestane tab verapamil SR cap flutamide cap verapamil SR tab letrozole tab verapamil tab megestrol susp CARDIAC GLYCOSIDES megestrol tab digoxin soln nilutamide tab digoxin tab tamoxifen tab CARDIOVASCULAR AGENTS - MISC. BETA BLOCKERS amlodipine/atorvastatin tab • Note: The list is subject to change. Please always refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com navitus.com Share a Clear View CONTRACEPTIVES NATAZIA TAB amethyst tab necon tab apri tab necon tab 1/50 aranelle tab norethindrone tab aviane tab NORINYL TAB 1/50 BEYAZ TAB nortrel tab CERVICAL CAP NUVARING cesia tab OGESTREL TAB CONCEPTROL GEL PARAGARD IUD CONTRACEPTIVE FILM PLAN B TAB CONTRACEPTIVE FOAM TODAY SPONGE CONTRACEPTIVE GEL tri-legest tab CONTRACEPTIVE SUPP tri-nessa (LO) tab cryselle tab vcf vaginal gel DEPO-PROVERA SC INJ 104MG wymzya FE tab DIAPHRAGM XULANE PATCH ELLA TAB YASMIN TAB enpresse tab YAZ TAB FEMALE CONDOMS DIABETIC SUPPLIES jolessa tab/ amethia tab alcohol pads junel FE tab blood/urine test strips junel tab lancet devices and lancets kariva tab needles and syringes kelnor tab DIURETICS levonorgestrel tab acetazolamide ER cap LEVONORGESTREL TAB 0.75MG acetazolamide tab LEVONORGESTREL/ETHINYL ESTRADIOL amiloride tab TAB amiloride/hydrochlorothiazide tab LO LOESTRIN TAB bumetanide tab LO MINASTRIN 24 FE CHEW TAB chlorothiazide tab LOESTRIN 24 FE TAB ethacrynic tab medroxyprogesterone inj furosemide tab mibelas chew tab hydrochlorothiazide cap MIRENA IUD hydrochlorothiazide tab mononessa tab indapamide tab • Note: The list is subject to change. Please always refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com navitus.com Share a Clear View methazolamide tab LURIDE SOLN metolazone tab phospha 250 neutral tab spironolactone tab potassium bicarbonate effer tab spironolactone/hydrochlorothiazide tab potassium chloride effer tab torsemide tab potassium chloride ER cap triamterene/hydrochlorothiazide cap potassium chloride micro tab triamterene/hydrochlorothiazide tab potassium chloride powder packet ENDOCRINE AND METABOLIC AGENTS - potassium chloride soln MISC. sodium fluoride chew tab alendronate tab SODIUM FLUORIDE LOZENGE calcitonin nasal spray sodium fluoride soln etidronate disodium tab 200mg SODIUM FLUORIDE TAB ibandronate tab 150mg zinc sulfate cap risedronate DR tab MOUTH/THROAT/DENTAL AGENTS risedronate tab chlorhexidine gluconate soln GOUT AGENTS sodium fluoride cream allopurinol tab sodium fluoride gel colchicine/probenecid tab sodium fluoride paste probenecid tab sodium fluoride rinse HEMATOLOGICAL AGENTS - MISC. sodium fluoride/potassium nitrate paste anagrelide cap triamcinolone in orabase paste aspirin/dipyridamole cap PSYCHOTHERAPEUTIC COMBINATION cilostazol tab AGENTS clopidogrel tab 75mg chlordiazepoxide/amitriptyline tab dipyridamole tab olanzapine/ fluoxetine cap pentoxifylline ER tab SMOKING CESSATION LAXATIVES bupropion SR tab lactulose soln CHANTIX PAK peg 3350/electrolytes soln CHANTIX TAB trilyte soln NICODERM PATCH MINERALS & ELECTROLYTES NICORETTE GUM FLUORABON SOLN NICORETTE LOZENGE FLUOR-A-DAY CHEW TAB nicotine gum LURIDE CHEW TAB NICOTINE KIT • Note: The list is subject to change. Please always refer to your Navitus formulary for a complete list of covered products. CUSTOMER CARE: 24 HOURS A DAY, 7 DAYS A WEEK | www.navitus.com navitus.com Share a Clear View nicotine lozenge MENVEO INJ nicotine patch M-M-R II INJ NICOTROL INHALER PNEUMOVAX INJ NICOTROL NASAL
Recommended publications
  • United States Patent Office Patented Sept

    United States Patent Office Patented Sept

    3,000,702 United States Patent Office Patented Sept. 19, 196 2 since potassium fluoride is very soluble. In this case, a 3,000,702 MANUEFACTURE OF SODIUM FLUOR DE double or complex salt is formed in the melt between George L. Cunningham, Burtonsville, Md., assignor to potassium fluoride and the calcium salt and that is slowly W. R. Grace & Co., New York, N.Y., a corporation extracted with water in spite of the great solubility of of Connecticut potassium fluoride in water. The corrosion of the molten No Drawing. Filed May 23, 1958, Ser. No. 737,196 melt is also a considerable problem although suitable 4. Claims. (CI. 23-88) ceramic materials have been discovered for constructing the fusion vessel. This invention relates to a process for the manufac Processes have been devised for the production of so ture of sodium fluoride relatively low in silica content. 10 dium fluoride based on the thermal decomposition of More particularly, this invention relates to a cyclic proc sodium silicofluoride to sodium fluoride and silicon tetra ess whereby sodium fluoride, relatively low in silica con fluoride (U.S. 1,896,697, U.S. 2,588,786, 1,730,915, tent and ammonium chloride, may be manufactured from 2,602,726, and U.S. 1,664,348). These processes are cheap and readily available raw materials. faulty in that relatively high temperatures are required to As manufactured at the present time, technical sodium 15 decompose the sodium silicofluoride and thus it is very fluoride contains 94% to 97% NaF and 1.5% to 5.0% difficult to carry the reaction to completion.
  • Clinical and Microbiological Study

    Clinical and Microbiological Study

    J Clin Exp Dent. 2015;7(5):e569-75. Combined mouthrinse in orthodontics Journal section: Oral Medicine and Pathology doi:10.4317/jced.51979 Publication Types: Research http://dx.doi.org/10.4317/jced.51979 Combined chlorhexidine-sodiumfluoride mouthrinse for orthodontic patients: Clinical and microbiological study Mahboobe Dehghani 1, Mostafa Abtahi 2, Hamed Sadeghian 3, Hooman Shafaee 1, Behrad Tanbakuchi 4 1 Assistant professor of orthodontics, Dental research center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran 2 Associate professor of orthodontics, Dental research center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran 3 Pathologist, Department of general Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 4 Assistant professor of orthodontics, Department of orthodontics, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran Correspondence: Mostafa Abtahi Dental Research Center School of Dentistry Dehghani M, Abtahi M, Sadeghian H, Shafaee H, Tanbakuchi B. Com-Com- Mashhad University of Medical Sciences bined chlorhexidine-sodiumfluoride mouthrinse for orthodontic patients: Park Square, Vakilabad Blvd., Mashhad, Iran Clinical and microbiological study. J Clin Exp Dent. 2015;7(5):e569-75. [email protected] http://www.medicinaoral.com/odo/volumenes/v7i5/jcedv7i5p569.pdf Article Number: 51979 http://www.medicinaoral.com/odo/indice.htm © Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488 Received: 24/08/2014 eMail: [email protected] Accepted: 11/12/2014 Indexed in: Pubmed Pubmed Central® (PMC) Scopus DOI® System Abstract Background: Orthodontic appliances impede good dental plaque control by brushing. Antimicrobial mouth rinses were suggested to improve this performance. We therefore aimed to investigate the effects of combined mouthrinse containing chlorhexidine (CHX) and sodium fluoride (NaF) on clinical oral hygiene parameters,and plaque bacte- rial level.
  • Co-Operative Effect of Exogenous Dextranase and Sodium Fluoride On

    Co-Operative Effect of Exogenous Dextranase and Sodium Fluoride On

    Journal of Dental Sciences (2016) 11,41e47 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-jds.com ORIGINAL ARTICLE Co-operative effect of exogenous dextranase and sodium fluoride on multispecies biofilms Yuan-xin Qiu a,b,cy, Meng-ying Mao a,by, Dan Jiang d, Xiao Hong a,b, Ying-ming Yang a,b, Tao Hu a,b* a Department of Preventive Dentistry, State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China b Department of Operative Dentistry and Endodontics, State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China c Department of Operative Dentistry and Endodontics, Tianjin Stomatological Hospital, Tianjin, China d Department of Operative Dentistry and Endodontics, The Affiliated Hospital of Stomatology, Chongqing Medical University, Chongqing, China Received 22 June 2015; Final revision received 4 August 2015 Available online 21 November 2015 KEYWORDS Abstract Background/purpose: The co-operative effect of exogenous dextranase (Dex) and confocal laser sodium fluoride (NaF) on Streptococcus mutans monospecies biofilms is impressive. Here we scanning investigated the effects of the combination on a mature cariogenic multispecies biofilm and microscopy; analyzed the potential mechanism. dextranase; Materials and methods: A multispecies biofilm of S. mutans, Lactobacillus acidophilus,and multispecies Actinomyces viscosus was established in vitro. Dex and NaF were added separately or cariogenic biofilm; together. The effects of the agents on the biomass were measured. The exopolysaccharide sodium fluoride; production was determined with the scintillation counting method. The viability and viability value morphology were evaluated using colony forming unit and confocal laser scanning micro- scopy, respectively.
  • Retention of Long-Term Interim Restorations with Sodium Fluoride Enriched Interim Cement Carolyn Strash Marquette University

    Retention of Long-Term Interim Restorations with Sodium Fluoride Enriched Interim Cement Carolyn Strash Marquette University

    Marquette University e-Publications@Marquette Master's Theses (2009 -) Dissertations, Theses, and Professional Projects Retention Of Long-Term Interim Restorations With Sodium Fluoride Enriched Interim Cement Carolyn Strash Marquette University Recommended Citation Strash, Carolyn, "Retention Of Long-Term Interim Restorations With Sodium Fluoride Enriched Interim Cement" (2013). Master's Theses (2009 -). Paper 201. http://epublications.marquette.edu/theses_open/201 RETENTION OF LONG-TERM INTERIM RESTORATIONS WITH SODIUM FLUORIDE ENRICHED INTERIM CEMENT by Carolyn Strash, D.D.S. A Thesis submitted to the Faculty of the Graduate School, Marquette University, in Partial Fulfillment of the Requirements for the Degree of Master of Science Milwaukee, Wisconsin May 2013 ABSTRACT RETENTION OF LONG-TERM INTERIM RESTORATIONS WITH SODIUM FLUORIDE ENRICHED INTERIM CEMENT Carolyn Strash, DDS Marquette University, 2013 Purpose: Interim fixed dental prostheses, or “provisional restorations”, are fabricated to restore teeth when definitive prostheses are made indirectly. Patients undergoing extensive prosthodontic treatment frequently require provisionalization for several months or years. The ideal interim cement would retain the restoration for as long as needed and still allow for ease of removal. It would also avoid recurrent caries by preventing demineralization of tooth structure. This study aims to determine if adding sodium fluoride varnish to interim cement may assist in the retention of interim restorations. Materials and methods: stainless steel dies representing a crown preparation were fabricated. Provisional crowns were milled for the dies using CAD/CAM technology. Crowns were provisionally cemented onto the dies using TempBond NE and NexTemp provisional cements as well as a mixture of TempBond NE and Duraphat fluoride varnish. Samples were stored for 24h then tested or thermocycled for 2500 or 5000 cycles before being tested.
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • Drug Prescribing for Dentistry Dental Clinical Guidance

    Drug Prescribing for Dentistry Dental Clinical Guidance

    Scottish Dental Clinical Effectiveness Programme SDcep Drug Prescribing For Dentistry Dental Clinical Guidance Second Edition August 2011 Scottish Dental Clinical Effectiveness Programme SDcep The Scottish Dental Clinical Effectiveness Programme (SDCEP) is an initiative of the National Dental Advisory Committee (NDAC) and is supported by the Scottish Government and NHS Education for Scotland. The programme aims to provide user-friendly, evidence-based guidance for the dental profession in Scotland. SDCEP guidance is designed to help the dental team provide improved care for patients by bringing together, in a structured manner, the best available information that is relevant to priority areas in dentistry, and presenting this information in a form that can interpreted easily and implemented. ‘Supporting the dental team to provide quality patient care’ Scottish Dental Clinical Effectiveness Programme SDcep Drug Prescribing For Dentistry Dental Clinical Guidance Second Edition August 2011 Drug Prescribing For Dentistry © Scottish Dental Clinical Effectiveness Programme SDCEP operates within NHS Education for Scotland. You may copy or reproduce the information in this document for use within NHS Scotland and for non-commercial educational purposes. Use of this document for commercial purpose is permitted only with written permission. ISBN 978 1 905829 13 2 First published 2008 Second edition published August 2011 Scottish Dental Clinical Effectiveness Programme Dundee Dental Education Centre, Frankland Building, Small’s Wynd, Dundee DD1
  • United States Patent (19) 11 Patent Number: 4,828,822 Miihlemann Et Al

    United States Patent (19) 11 Patent Number: 4,828,822 Miihlemann Et Al

    United States Patent (19) 11 Patent Number: 4,828,822 Miihlemann et al. (45) Date of Patent: May 9, 1989 (54) PROCESS FOR STABILIZING AQUEOUS S. Ebell, "Karies und Zuckeraustauschstoffe', Emah COMPOSITIONS CONTAINING T N SALTS rungsclorschung Hett, 1978, pp. 171-174. 75) Inventors: Hans R. Miihlemann, Zollikon; Hans H. R. Muhlemann, "Zuckerfreie, Zahnschonende und Schmid, Muttenz, both of Nicht-Kariogene Bonbons und Sussigkeiten'. Switzerland 88, Scand J. Dent. Res., 193-200 (1980), “Effect of Mouthrinses With Tin(II), Fluoride, Lanthanum Chlo 73) Assignee: GABA International AG, Basel, ride, Sodium Fluoride and Chlorohexidine on the Switzerland Amount of Lipoteichoic Acid Formed in Plaque'. (21) Appl. No.: 109,830 Substitution of Sucrose by Lycasin in Candy, Roslagen Study, Frostell et al., Acta Odontol. Scand., 1974, 32(4), 22 Filed: Oct. 16, 1987 235-54 (Eng), 71769m, CA 82-71769. Chemical Abstract, 80-128408h, Effect of Mouth Related U.S. Application Data Rinses with Sucrose, Glucose, Fructose, Lactose, Sor 63 Continuation-in-part of Ser. No. 363,013, Mar. 29, bitol, and Lycasin on the pH of Dental Plaque. 1982, abandoned, which is a continuation of Ser. No. Chemical Abstracts, 93-106820c, Effect of Inorganic 192,874, Oct. 1, 1980, abandoned. Ions and Surface Active Organic Compounds on the (30) Foreign Application Priority Data Adherence of Oral Streptococci. Oct. 2, 1979 GB United Kingdom ................. 7934159 Chemical Abstract, 93:43218q, Relation of Amylase to Starch and Lycasin Metabolism in Human Dental Jan. 24, 1980 GB United Kingdom ................. 8002433 Plaque in Vitro. Feb. 1, 1980 GB United Kingdom ................. 8003525 Fed. Reg. 17,245(1974).
  • Free PDF Download

    Free PDF Download

    European Review for Medical and Pharmacological Sciences 2012; 16: 1611-1636 The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina A. DI MONACO, A. SESTITO Department of Cardiology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy Abstract. – Ischemic heart disease (IHD) is a serve is exhausted2. Symptom severity can be major cause of death in Western Countries and modulated by dynamic vasomotion at the site of accounts for very high costs worldwide. In this re- stenoses and/or by coronary microvascular dys- view we discussed the pathogenesis, symptoms, 1,2 diagnosis, prognosis and management of chronic function . IHD. In particular, we discussed about the percu- In microvascular angina transient myocardial taneous coronary interventions and coronary ischemia is caused by coronary microvascular artery bypass grafting, as well as to clinical trials dysfunction in patients with angiographically that evaluated the advantages of one approach normal epicardial coronary arteries, in the ab- versus another. Pharmacological treatment is 3,4 among major objectives of the review and for sence of any other specific cardiac disease . In each class of therapeutic agents an evaluation of vasospastic angina transient myocardial is- well-conducted clinical trials is provided. The chemia is caused by coronary spasm5. most important drug classes in IHD treatment are Furthermore, angina and transient myocardial betablockers, calcium channel blockers, nitrates, ischemia may also occur in patients with non ath- antiplatelet agents, and ACE-inhibitors. In addition to these agents, also new treatment options are erosclerotic obstructive coronary artery disease, evaluated in patients with stable IHD.
  • Sodium Fluoride Jtbaker.Pdf

    Sodium Fluoride Jtbaker.Pdf

    MSDS Number: S3722 * * * * * Effective Date: 03/14/11 * * * * * Supersedes: 09/23/09 SODIUM FLUORIDE 1. Product Identification Synonyms: Floridine; sodium monofluoride; disodium difluoride; natrium fluoride; Florocid CAS No.: 7681-49-4 Molecular Weight: 41.99 Chemical Formula: NaF Product Codes: J.T. Baker: 3687, 3688, 3689 Macron: 0467, 5309, 5325, 7636 2. Composition/Information on Ingredients Ingredient CAS No Percent Hazardous --------------------------------------- ------------ ------------ --------- Sodium Fluoride 7681-49-4 100% Yes 3. Hazards Identification Emergency Overview -------------------------- DANGER! MAY BE FATAL IF SWALLOWED OR INHALED. AFFECTS RESPIRATORY SYSTEM, HEART, SKELETON, CIRCULATORY SYSTEM, CENTRAL NERVOUS SYSTEM AND KIDNEYS. CAUSES IRRITATION TO SKIN, EYES AND RESPIRATORY TRACT. IRRITATION EFFECTS MAY BE DELAYED. SAF-T-DATA(tm) Ratings (Provided here for your convenience) ----------------------------------------------------------------------------------------------------------- Health Rating: 3 - Severe (Poison) Flammability Rating: 0 - None Reactivity Rating: 1 - Slight Contact Rating: 3 - Severe Lab Protective Equip: GOGGLES & SHIELD; LAB COAT & APRON; VENT HOOD; PROPER GLOVES Storage Color Code: Blue (Health) ----------------------------------------------------------------------------------------------------------- Potential Health Effects ---------------------------------- If inhaled or swallowed, this compound can cause fluoride poisoning. Early symptoms include nausea, vomiting, diarrhea, and weakness.
  • Sodium Fluoride-Induced Oxidative Stress and Histological Changes in Liver of Swiss Albino Mice and Amelioration by Ocimum Sanctum Linn

    Sodium Fluoride-Induced Oxidative Stress and Histological Changes in Liver of Swiss Albino Mice and Amelioration by Ocimum Sanctum Linn

    Online - 2455-3891 Vol 11, Issue 9, 2018 Print - 0974-2441 Research Article SODIUM FLUORIDE-INDUCED OXIDATIVE STRESS AND HISTOLOGICAL CHANGES IN LIVER OF SWISS ALBINO MICE AND AMELIORATION BY OCIMUM SANCTUM LINN. BHAGWENDRA PRAKASH, SURESH KUMAR SABAL, RAJBALA VERMA, JOHN PJ, INDERPAL SONI* Department of Zoology, Environmental Toxicology Laboratory, Centre for Advanced Studies, University of Rajasthan, Jaipur, Rajasthan, India. Email: [email protected]; [email protected] Received: 20 April 2018, Revised and Accepted: 19 May 2018 ABSTRACT Objective: The present study was designed to evaluate hepatotoxicity induced by sodium fluoride (NaF) in Swiss albino mice and amelioration by Ocimum sanctum Linn. Methods: Mice were divided into six groups, Group I received tap water, Group II received low dose of NaF (8 mg/L), Group III high dose of NaF (80 mg/L) in drinking water, Group IV tap water along with 250 mg/kg body weight/day leaf extract of O. sanctum Linn., Group V 8 mg/L NaF in drinking water and 250 mg/kg body weight leaf extract of O. sanctum Linn., and Group VI 80 mg/L NaF in drinking water along with leaf extract of O. sanctum Linn. 250 mg/kg body weight/day for 90 days. On the 91st day, the animals were autopsied and liver tissue samples were taken to assess histopathological changes and oxidative stress by estimating glutathione peroxidase, superoxide dismutase, and catalase. Results: A highly significant decrease in the activity of antioxidant enzymes occurred with the high dose (Group III). Hepatic histopathological architecture exhibited deformities, namely, ballooning, hypertrophy, hepatocellular necrosis, infiltration of mononuclear cells, deformed central vein, sinusoidal dilation, and binucleated cells.
  • Selected Medicines Used in Iontophoresis

    Selected Medicines Used in Iontophoresis

    pharmaceutics Review Selected Medicines Used in Iontophoresis Tomasz M. Karpi ´nski Department of Medical Microbiology, Pozna´nUniversity of Medical Sciences, Wieniawskiego 3, 61-712 Pozna´n,Poland; [email protected] or [email protected]; Tel.: +48-61-854-61-38 Received: 19 September 2018; Accepted: 24 October 2018; Published: 25 October 2018 Abstract: Iontophoresis is a non-invasive method of systemic and local drug delivery using an electric field. Iontophoresis enables diffusion of the selected drug via skin, mucosa, enamel, dentin, and other tissues. The amount of delivered therapeutic molecules is about 10–2000 times greater than conventional forms of delivery. Among other fields, this method is used in dentistry, ophthalmology, otorhinolaryngology, and dermatology. According to related literature, the most important drugs studied or administered by iontophoresis are: Local anesthetics, opioids, steroids, non-steroidal anti-inflammatory drugs, antibacterial drugs, antifungal drugs, antiviral drugs, anticancer drugs, fluorides, and vitamins. The present review covers current available data regarding the selected medicines used in iontophoresis. Furthermore, indications and conditions of iontophoresis application are reviewed. Keywords: iontophoresis; drug delivery; dentistry; ophthalmology; local anaesthetics; non-steroid anti-inflammatory drugs; antibiotics; anticancer drugs 1. Introduction Iontophoresis is a type of electrotherapy, during which a drug is introduced deep into the tissues as a means of systemic and local drug application [1]. It is based on the principle that in a given electric field, positively charged drug ions (cations) are repelled by a positive electrode (anode) and are directed to the cathode (Figure1). In turn, negative ions (anions, e.g., ketoprofen) being repelled by the negative electrode (cathode), follow the anode.
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al

    (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al

    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.